Yuki Yamamoto
Chief Executive Officer HiLung Inc
Seminars
Thursday 14th May 2026
Predicting Lung Toxicity Using Complex In Vitro Models
9:30 am
- Leveraging HiLung’s iPSC‑based technology, we develop lung CIVMs that include organoids as well as immune cells such as tissue‑resident alveolar macrophages to accelerate drug discovery.
- Our system enables pathophysiologically relevant assays through organoid histopathology and biomarker analyses
- Overview of ADC toxicity evaluation at HiLung as an application of lung CIVMs
